Tibet Rhodiola Pharmaceutical Holding Co (600211) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.072x

Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) has a cash flow conversion efficiency ratio of 0.072x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥297.86 Million ≈ $43.59 Million USD) by net assets (CN¥4.17 Billion ≈ $609.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Tibet Rhodiola Pharmaceutical Holding Co fund operations to measure how many days the company can operate on defensive assets alone.

Tibet Rhodiola Pharmaceutical Holding Co - Cash Flow Conversion Efficiency Trend (1999–2025)

This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tibet Rhodiola Pharmaceutical Holding Co Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tibet Rhodiola Pharmaceutical Holding Co ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Eco World Develop Group KLSE:8206	0.031x
Tri Continental Closed Fund NYSE:TY	-0.167x
Guangzhou Goaland Energy Conservation Tech Co Ltd SHE:300499	0.026x
H2O America NASDAQ:HTO	0.051x
MCC Meili Paper Industry Co Ltd SHE:000815	0.059x
Integral Ad Science Holding LLC NASDAQ:IAS	0.044x
Harbin Boshi Automation Co Ltd SHE:002698	0.011x
Kingsignal Technology Co Ltd SHE:300252	-0.001x

Annual Cash Flow Conversion Efficiency for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)

The table below shows the annual cash flow conversion efficiency of Tibet Rhodiola Pharmaceutical Holding Co from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Tibet Rhodiola Pharmaceutical Holding Co.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥4.17 Billion ≈ $609.56 Million	CN¥1.03 Billion ≈ $150.24 Million	0.246x	-2.08%
2024-12-31	CN¥3.95 Billion ≈ $578.32 Million	CN¥994.79 Million ≈ $145.57 Million	0.252x	-21.53%
2023-12-31	CN¥3.37 Billion ≈ $493.67 Million	CN¥1.08 Billion ≈ $158.35 Million	0.321x	+16.10%
2022-12-31	CN¥3.03 Billion ≈ $443.50 Million	CN¥837.38 Million ≈ $122.53 Million	0.276x	+99.38%
2021-12-31	CN¥2.65 Billion ≈ $387.05 Million	CN¥366.53 Million ≈ $53.64 Million	0.139x	-16.23%
2020-12-31	CN¥2.59 Billion ≈ $378.76 Million	CN¥428.17 Million ≈ $62.65 Million	0.165x	-17.33%
2019-12-31	CN¥2.45 Billion ≈ $358.04 Million	CN¥489.59 Million ≈ $71.64 Million	0.200x	+56.16%
2018-12-31	CN¥2.26 Billion ≈ $330.29 Million	CN¥289.22 Million ≈ $42.32 Million	0.128x	+186.57%
2017-12-31	CN¥2.05 Billion ≈ $299.31 Million	CN¥91.46 Million ≈ $13.38 Million	0.045x	-88.24%
2016-12-31	CN¥658.19 Million ≈ $96.31 Million	CN¥250.21 Million ≈ $36.61 Million	0.380x	+37.92%
2015-12-31	CN¥485.90 Million ≈ $71.10 Million	CN¥133.93 Million ≈ $19.60 Million	0.276x	+180.74%
2014-12-31	CN¥414.18 Million ≈ $60.61 Million	CN¥-141.40 Million ≈ $-20.69 Million	-0.341x	-148.81%
2013-12-31	CN¥399.20 Million ≈ $58.42 Million	CN¥279.22 Million ≈ $40.86 Million	0.699x	+379.69%
2012-12-31	CN¥385.44 Million ≈ $56.40 Million	CN¥56.20 Million ≈ $8.22 Million	0.146x	+328.05%
2011-12-31	CN¥354.94 Million ≈ $51.94 Million	CN¥12.09 Million ≈ $1.77 Million	0.034x	+481.16%
2010-12-31	CN¥324.19 Million ≈ $47.44 Million	CN¥1.90 Million ≈ $278.05K	0.006x	-90.17%
2009-12-31	CN¥300.00 Million ≈ $43.90 Million	CN¥17.88 Million ≈ $2.62 Million	0.060x	-22.44%
2008-12-31	CN¥279.15 Million ≈ $40.85 Million	CN¥21.46 Million ≈ $3.14 Million	0.077x	+215.24%
2007-12-31	CN¥274.28 Million ≈ $40.14 Million	CN¥-18.30 Million ≈ $-2.68 Million	-0.067x	-178.61%
2006-12-31	CN¥396.34 Million ≈ $58.00 Million	CN¥33.63 Million ≈ $4.92 Million	0.085x	+76.37%
2005-12-31	CN¥393.25 Million ≈ $57.54 Million	CN¥18.92 Million ≈ $2.77 Million	0.048x	-22.12%
2004-12-31	CN¥435.51 Million ≈ $63.73 Million	CN¥26.90 Million ≈ $3.94 Million	0.062x	-44.44%
2003-12-31	CN¥424.53 Million ≈ $62.12 Million	CN¥47.20 Million ≈ $6.91 Million	0.111x	+41.76%
2002-12-31	CN¥418.85 Million ≈ $61.29 Million	CN¥32.85 Million ≈ $4.81 Million	0.078x	+106.06%
2001-12-31	CN¥406.50 Million ≈ $59.48 Million	CN¥15.47 Million ≈ $2.26 Million	0.038x	-25.49%
2000-12-31	CN¥402.35 Million ≈ $58.88 Million	CN¥20.55 Million ≈ $3.01 Million	0.051x	+786.04%
1999-12-31	CN¥389.71 Million ≈ $57.03 Million	CN¥2.25 Million ≈ $328.81K	0.006x	--

About Tibet Rhodiola Pharmaceutical Holding Co

SHG:600211 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.74 Billion

CN¥11.86 Billion CNY

Market Cap Rank

#6786 Global

#1505 in China

Share Price

CN¥36.80

Change (1 day)

+0.96%

52-Week Range

CN¥35.31 - CN¥56.43

All Time High

CN¥165.99